Cargando…

G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo

BACKGROUND: The glucose-6-phosphatase catalytic subunit (G6PC) is a key enzyme that is involved in gluconeogenesis and glycogen decomposition during glycometabolism. Studies have shown that G6PC is abnormally expressed in various cancers and participates in the proliferation and metastasis of tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Kun, Deng, Chunling, Du, Pan, Liu, Taorui, Piao, Junjie, Piao, Yingshi, Yang, Meng, Chen, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915493/
https://www.ncbi.nlm.nih.gov/pubmed/35277194
http://dx.doi.org/10.1186/s12958-022-00921-6
_version_ 1784668035178561536
author Zhu, Kun
Deng, Chunling
Du, Pan
Liu, Taorui
Piao, Junjie
Piao, Yingshi
Yang, Meng
Chen, Liyan
author_facet Zhu, Kun
Deng, Chunling
Du, Pan
Liu, Taorui
Piao, Junjie
Piao, Yingshi
Yang, Meng
Chen, Liyan
author_sort Zhu, Kun
collection PubMed
description BACKGROUND: The glucose-6-phosphatase catalytic subunit (G6PC) is a key enzyme that is involved in gluconeogenesis and glycogen decomposition during glycometabolism. Studies have shown that G6PC is abnormally expressed in various cancers and participates in the proliferation and metastasis of tumors. However, the role of G6PC in cervical cancer remains poorly established. METHODS: To analyze the expression of G6PC in cervical cancer tissues in patients by immunohistochemistry. Effects of G6PC deregulation on cervical cancer phenotype were determined using MTT, colony formation, transwell, and wound-healing assays. And constructed a nude mouse xenograft tumor model and CAM assay in vivo. The effect of G6PC on glycolysis in cervical cancer was also evaluated. Effect of G6PC on PI3K/AKT/mTOR pathway was detected by Western blot assay. RESULTS: In this study, G6PC expression was found to be upregulated in cervical cancer tissues, and this upregulated expression was associated with LN metastasis, clinical stage, recurrence, and disease-free survival and overall survival rates, indicating that G6PC could serve as a novel marker of early diagnosis in cervical cancer. G6PC promoted proliferation, invasion, epithelial mesenchymal transition (EMT) progression, and angiogenesis of cervical cancer cells. Mechanistically, G6PC activated PI3K/AKT/mTOR pathways. The PI3K/AKT pathway inhibitor, LY294002 could partially attenuate the effect. CONCLUSIONS: G6PC plays a key role in the progression of cervical cancer, and overexpressed G6PC is closely related to patient LN metastasis, clinical stage, recurrence and shortened survival. G6PC promoted cervical cancer proliferation, invasion, migration, EMT progression, and angiogenesis, partially through activating the PI3K/AKT pathway. G6PC, as a metabolic gene, not only plays a role in metabolism, but also participates in the development of cervical cancer. Its complex metabolic and non metabolic effects may be a potential therapeutic target and worthy of further study.
format Online
Article
Text
id pubmed-8915493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89154932022-03-18 G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo Zhu, Kun Deng, Chunling Du, Pan Liu, Taorui Piao, Junjie Piao, Yingshi Yang, Meng Chen, Liyan Reprod Biol Endocrinol Research BACKGROUND: The glucose-6-phosphatase catalytic subunit (G6PC) is a key enzyme that is involved in gluconeogenesis and glycogen decomposition during glycometabolism. Studies have shown that G6PC is abnormally expressed in various cancers and participates in the proliferation and metastasis of tumors. However, the role of G6PC in cervical cancer remains poorly established. METHODS: To analyze the expression of G6PC in cervical cancer tissues in patients by immunohistochemistry. Effects of G6PC deregulation on cervical cancer phenotype were determined using MTT, colony formation, transwell, and wound-healing assays. And constructed a nude mouse xenograft tumor model and CAM assay in vivo. The effect of G6PC on glycolysis in cervical cancer was also evaluated. Effect of G6PC on PI3K/AKT/mTOR pathway was detected by Western blot assay. RESULTS: In this study, G6PC expression was found to be upregulated in cervical cancer tissues, and this upregulated expression was associated with LN metastasis, clinical stage, recurrence, and disease-free survival and overall survival rates, indicating that G6PC could serve as a novel marker of early diagnosis in cervical cancer. G6PC promoted proliferation, invasion, epithelial mesenchymal transition (EMT) progression, and angiogenesis of cervical cancer cells. Mechanistically, G6PC activated PI3K/AKT/mTOR pathways. The PI3K/AKT pathway inhibitor, LY294002 could partially attenuate the effect. CONCLUSIONS: G6PC plays a key role in the progression of cervical cancer, and overexpressed G6PC is closely related to patient LN metastasis, clinical stage, recurrence and shortened survival. G6PC promoted cervical cancer proliferation, invasion, migration, EMT progression, and angiogenesis, partially through activating the PI3K/AKT pathway. G6PC, as a metabolic gene, not only plays a role in metabolism, but also participates in the development of cervical cancer. Its complex metabolic and non metabolic effects may be a potential therapeutic target and worthy of further study. BioMed Central 2022-03-11 /pmc/articles/PMC8915493/ /pubmed/35277194 http://dx.doi.org/10.1186/s12958-022-00921-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhu, Kun
Deng, Chunling
Du, Pan
Liu, Taorui
Piao, Junjie
Piao, Yingshi
Yang, Meng
Chen, Liyan
G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
title G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
title_full G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
title_fullStr G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
title_full_unstemmed G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
title_short G6PC indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
title_sort g6pc indicated poor prognosis in cervical cancer and promoted cervical carcinogenesis in vitro and in vivo
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915493/
https://www.ncbi.nlm.nih.gov/pubmed/35277194
http://dx.doi.org/10.1186/s12958-022-00921-6
work_keys_str_mv AT zhukun g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT dengchunling g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT dupan g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT liutaorui g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT piaojunjie g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT piaoyingshi g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT yangmeng g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo
AT chenliyan g6pcindicatedpoorprognosisincervicalcancerandpromotedcervicalcarcinogenesisinvitroandinvivo